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Human B regs?
If T cells can be regulatory, why not 
B cells? This proposition has piqued 
the interest of Sudhir Gupta (Univer-
sity of California, Irvine, CA) since 
regulatory T cells were 
first identified. A grow-
ing body of evidence 
now supports the ex-
istence of regulatory 
B cells (B regs), and 
Gupta’s presentation pro-
vided the first data 
suggesting their existence in humans.
Previous studies of mouse models of 
autoimmune disorders have indicated 
that certain subsets of B cells are capable 
of immune suppression and thus relief of 
disease symptoms. But, “nobody looked 
from the point of view of purifying the 
B cells themselves,” explained Gupta. 
Furthermore, nobody had looked for 
human regulatory B cells.
Gupta and colleagues have a 
long-standing interest 
in memory T cells, so 
as a starting point they 
looked at the effect of 
isolated human B cells on 
memory T cell develop-
ment. Activation of 
naive T cells in culture 
promotes proliferation 
and then differentiation 
into central memory and effector memory 
T cells. But coculturing these cells in a 
particular way with activated B cells, 
Gupta showed, specifically inhibited the 
production of effector memory T cells.
It is unclear as yet whether the B cells 
inhibit the differentiation or proliferation 
of effector memory T cells. It is clear, 
however, that the lack of effector memory 
T cells was not a result of apoptosis. What’s 
also clear is that the B cells inhibit the 
T cells by using both a soluble factor 
(or factors) and cell–cell contact.
The team is currently determining 
which subset of human B cells are re-
sponsible for effector memory T cell 
inhibition and investigating whether 
B regs can suppress other subsets of T 
cells or other immune cell types. 
Reference: Mizoguchi, A., and A. K. Bhan. 2006. 
J. Immunol. 176:705–710.
Could CD44 signal death in diabetes?
CD44 is implicated in a number of autoimmune diseases, including insulin-
dependent diabetes. Despite CD44’s proinflammatory capacity, however, 
inflammation might not be its only pathological mechanism. According to a 
presentation by David Naor (Hebrew University, Jerusalem, Israel), in diabetes 
CD44 might also transmit apoptotic signals that kill off insulin-producing 
pancreatic cells.
CD44 is a widely expressed cell surface protein that, among other functions, 
promotes cell migration by binding to extracellular matrix components. Its 
abundance on lymphocytes and neutrophils enables these cells to exit blood 
vessels and migrate to inflammation sites.
CD44 was implicated in diabetes when it was shown that blockade of CD44 
activity delayed or relieved symptoms in a mouse model of type I diabetes 
called NOD. Naor and colleagues considered that the relief might be due to the 
inability of inflammatory cells lacking CD44 to migrate to, and create havoc in, 
the pancreas.
When the team transferred splenocytes from CD44-deficient NOD mice to 
normal wild-type recipients, however, the recipient mice still developed 
diabetes, suggesting the CD44-lacking cells were able to migrate to the 
pancreas. Yet when they tried the reverse, transferring NOD splenocytes 
expressing CD44 into recipients that lacked CD44, most of the recipients never 
developed diabetes.
In addition to its migratory functions, CD44 can also transmit apoptotic 
signals. Apoptotic destruction of insulin-producing pancreatic islet cells is a 
hallmark of type I diabetes. Naor therefore predicts that, although another 
molecule may compensate for CD44’s migratory function, expression of CD44 on 
pancreatic islet cells might be required to deliver a direct death sentence.   
Reference: Weiss, L., et al. 2000. Proc. Natl. Acad. Sci. USA. 97:285–290.
The pancreatic islets of diabetics are invaded by 
inflammatory cells. Islet destruction requires CD44 
(brown) not for this invasion but for delivering 
apoptotic signals.
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Human B regs inhibit the production of 
effector memory T cells but not central 
memory T cells following naive T cell activation.
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Eating trash prevents lupus
Just as letting garbage accumulate can be a health risk, failure 
to clear-up dead and dying cells is a risk factor for lupus. Work 
presented by Martin Herrmann indicates why some lupus 
patients’ cells are not so good at taking out the trash.
The disposal of apoptotic cells is defective in approximately 
half of all lupus cases. As these cellular corpses decay, antigens 
that are normally hidden inside the cell become exposed to the 
immune system. This is thought to cause the production of 
autoantibodies against nuclear components, which is the main 
immunological characteristic of the disease.
Dying cells are normally eaten by phagocytes before their 
nuclear antigens are exposed. But the team found that 
phagocytes derived from blood stem cells of some lupus 
patients failed to gobble up artificial targets efficiently. This 
phagocytosis defect correlated with an adhesion defect, as 
the patients’ phagocytes were unable to bind regular plastic 
culture dishes. “The better the cells stick,” says Herrmann, 
“the better they eat.”
The cause of the adherence and 
phagocytosis defects is not yet 
known. Herrmann suspects that the 
patients’ blood stem cells might not 
be maturing correctly, as they initially 
appeared normal.
Failure to clear apoptotic cells is 
likely to be caused by different defects 
in different individuals. Although the 
adherence and phagocytosis defects 
were observed in approximately half of 
lupus patients, only phagocytosis was 
impaired in a smaller percentage. 
Herrmann also presented preliminary 
data suggesting that a failure of 
phagocytes to migrate toward 
apoptotic corpses could be to blame in 
some patients. 
Reference: Kuhn, A., et al. 2006. Arthritis 
Rheum. 54:939–950.
Lupus and the CD5 switch
New data presented by Yves Renaudineau (Brest University 
Medical School, Brest, France) unraveled a chain of events leading 
from cell cycle arrest to autoimmunity via the switching on of a 
defective B cell dampener.
Loss of this dampener, called CD5, makes mice prone to 
autoimmunity problems such as those experienced by lupus patients. 
CD5 is normally expressed on the cell surface, but Renaudineau and 
colleagues had previously identified an alternative transcript that 
produces a cytoplasmically retained form of the protein.
The cytoplasmic version arises from the inclusion of an upstream 
human endogenous retrovirus (HERV) element. Such retroviral 
elements are generally silenced by DNA 
methylation, but lupus has been linked to 
defective DNA methylation.
Renaudineau showed that the HERV-
CD5 promoter region was indeed under-
methylated in activated B cells from lupus 
patients. This was coupled with failed induc-
tion of the DNA methylator DNMT1. As a 
result, transcription of the cytoplasmic form 
of CD5 was strongly up-regulated. Too much 
cytoplasmic CD5 led to a decrease in cell 
surface CD5 expression.
The team blames the lack of DNMT1 
on a failure of the patient cells to efficiently 
proliferate upon activation, as DNMT1 is 
normally up-regulated in cycling cells. 
Renaudineau suggests that the resulting lack 
of surface CD5 expression makes the B cells 
prone to promiscuous activation and thus 
to autoantibody production. 
Reference: Renaudineau, Y., et al. 2005. Blood. 106:2781–9.
Macrophages clear up 
apoptotic trash (brown) 
from normal skin (top), but 
they fail to do so in some 
lupus patients (bottom).
Cell surface CD5 
(top) is reduced when 
hypomethylation in lupus 
B cells switches on an 
alternative cytoplasmic 
form (bottom).
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Sleeping LINEs
For the safety of the genome, endogenous retroviral 
sequences, such as LINEs, are kept caged by DNA 
methylation. But these cages are thrown open in 
rheumatoid arthritis (RA), according to a presentation 
by Steffen Gay (University Hospital, Zurich, Switzerland). 
The up-regulation of retroviral elements might thus be 
a common defect in autoimmunity (see also “Lupus and 
the CD5 switch”).
The destruction of bone and cartilage in RA is not 
solely the responsibility of immune cells. Synovial 
fibroblasts, which line the joints, also get activated and 
begin to aggressively attack the joints by producing 
matrix degrading enzymes as well as promoting the 
maturation of bone-destroying osteoclasts.
The discovery that synovial fibroblasts express Toll-
like receptors led the team to consider that 
transformation into this invasively growing, activated 
state might be triggered by an environmental agent. 
However, the combination of a decade’s unsuccessful 
hunting for such an agent, with new findings that 
synovial fibroblast activation is coupled with strong up-
regulation of retroviral LINEs, leads the team to now 
speculate that in fact these endogenous agents are to 
blame. DNA methylation was reduced in patient synovial 
fibroblasts, explaining how the LINEs are awakened.
Endogenous retroviral activation in these fibroblasts 
could explain why antiinflammatory treatment generally 
only slows joint destruction but rarely stops it altogether. 
Combining antiinflammatories with treatments that 
prevent the demethylation could prove to be a more 
effective remedy for RA. 
Reference: Karouzakis, E., et al. 2006. Immunol. Lett. 106:8–13.
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